

## United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.	
09/846,456	05/02/2001	Marie-Francoise Rosier-Montus	3806.0505	1457	
5487	7590 12/29/2005		EXAMINER		
ROSS J. O	ROSS J. OEHLER			SULLIVAN, DANIEL M	
AVENTIS P	HARMACEUTICALS	INC.			
ROUTE 202	-206		ART UNIT	PAPER NUMBER	
MAIL COD	E: D303A	1636			
BRIDGEWATER, NJ 08807			DATE MAILED: 12/29/2005		

Please find below and/or attached an Office communication concerning this application or proceeding.

## Advisory Action Before the Filing of an Appeal Brief

Application No	Applicant(s)	
09/846,456	ROSIER-MONTUS ET AL.	
Examiner	Art Unit	
Daniel M. Sullivan	1636	

	Daniel M. Sullivan	1636	
The MAILING DATE of this communication appe	ars on the cover sheet with the	correspondence add	ress
THE REPLY FILED <u>17 November 2005</u> FAILS TO PLACE THIS	APPLICATION IN CONDITION F	OR ALLOWANCE.	
1.   The reply was filed after a final rejection, but prior to or on this application, applicant must timely file one of the follow places the application in condition for allowance; (2) a No a Request for Continued Examination (RCE) in compliance time periods:	ving replies: (1) an amendment, af tice of Appeal (with appeal fee) in	fidavit, or other evider compliance with 37 C	ice, which FR 41.31; or (3)
<ul> <li>a)</li></ul>	dvisory Action, or (2) the date set forth	in the final rejection, whig date of the final rejecti	ichever is later. Ir on.
Examiner Note: If box 1 is checked, check either box (a) or ( TWO MONTHS OF THE FINAL REJECTION. See MPEP 70	06.07(f).		
Extensions of time may be obtained under 37 CFR 1.136(a). The date nave been filed is the date for purposes of determining the period of extunder 37 CFR 1.17(a) is calculated from: (1) the expiration date of the set forth in (b) above, if checked. Any reply received by the Office later may reduce any earned patent term adjustment. See 37 CFR 1.704(b) NOTICE OF APPEAL	tension and the corresponding amount shortened statutory period for reply orig than three months after the mailing da	of the fee. The appropri	ate extension fee ce action: or (2) as
2. The Notice of Appeal was filed on 17 November 2005. A of the date of filing the Notice of Appeal (37 CFR 41.37(a) appeal. Since a Notice of Appeal has been filed, any reply AMENDMENTS	), or any extension thereof (37 CF	R 41.37(e)), to avoid	dismissal of the
3. The proposed amendment(s) filed after a final rejection, l (a) They raise new issues that would require further con	nsideration and/or search (see NO	, will <u>not</u> be entered b TE below);	ecause
<ul> <li>(b) ☐ They raise the issue of new matter (see NOTE belo</li> <li>(c) ☒ They are not deemed to place the application in bet appeal; and/or</li> </ul>	ter form for appeal by materially re		the issues for
(d) ☐ They present additional claims without canceling a NOTE: <u>See Continuation Sheet</u> . (See 37 CFR 1.1		jected claims.	
1. The amendments are not in compliance with 37 CFR 1.12		ompliant Amendment	(PTOL-324).
5. Applicant's reply has overcome the following rejection(s)		•	,
<ol> <li>Newly proposed or amended claim(s) would be al non-allowable claim(s).</li> </ol>			_
7.  For purposes of appeal, the proposed amendment(s): a) how the new or amended claims would be rejected is provided that the status of the claim(s) is (or will be) as follows: Claim(s) allowed: Claim(s) objected to: Claim(s) rejected: 1-3 and 5-38.	☑ will not be entered, or b) ☐ wi vided below or appended.	ill be entered and an e	explanation of
Claim(s) withdrawn from consideration:			
AFFIDAVIT OR OTHER EVIDENCE			
<ol> <li>The affidavit or other evidence filed after a final action, bu because applicant failed to provide a showing of good and was not earlier presented. See 37 CFR 1.116(e).</li> </ol>	d sufficient reasons why the affidate	vit or other evidence is	necessary and
The affidavit or other evidence filed after the date of filing entered because the affidavit or other evidence failed to o showing a good and sufficient reasons why it is necessary	vercome all rejections under appe	al and/or appellant fai	Is to provide a
10.  The affidavit or other evidence is entered. An explanation REQUEST FOR RECONSIDERATION/OTHER	n of the status of the claims after e	ntry is below or attach	ned.
<ol> <li>The request for reconsideration has been considered bu <u>See Continuation Sheet.</u></li> </ol>	t does NOT place the application i	n condition for allowar	nce because:
<ul><li>12.  Note the attached Information Disclosure Statement(s).</li><li>13.  Other:</li></ul>	(PTO/SB/08 or PTO-1449) Paper N	No(s)	
		NO 00	
		DANIEL M. SUL	LIVAN

U.S. Patent and Trademark Office PTOL-303 (Rev. 7-05) PATENT EXAMINER

Continuation of 3. NOTE: Claims 2, 3 and 5, which were previously limited to comprising 500 or more consecutive nucleotides of SEQ ID NO: 1 by virtue of their dependence from claim 1 have been amended such that they are now independent of the limitations of claim 1 and, therefore, no longer required to comprise 500 or more consecutive nucleotides of SEQ ID NO: 1. The amendment expands the scope of the claims such that a new search and consideration of the claims for compliance under 35 U.S.C. §112 is necessitated. In the remarks, Applicant states in the previous dependence of the claims from claim 1 was improper because claim 1 featured 500 bases while the length of claim 2 is 357 bases. Likewise, Applicant asserts that claims 3 and 5 cannot depend from claim 1 because the claims recite that the polynucleotides comprise 20 and 35 nucleotides, respectively. However, it is noted that the claims depending from claim 1, as presented in the 15 February 2005 claim set, recite that they comprise the entirety of SEQ ID NO: 2, comprise a polynucleotide which has at least 20 consecutive nucleotides of SEQ ID NO: 3 or comprise a polynucleotide which has 35 or more consecutive nucleotides of the sequence SEQ ID NO: 5. Given that the polynucleotide of claim 1 and the polynucleotides of each of claims 2, 3 and 5 are claimed using open language and the size limitations in claims 2, 3 and 5 are set forth as lower limits the polynucleotides of the dependent claims are within the scope of independent claim 1. For example, a polynucleotide comprising 500 or more consecutive nucleotides of SEQ ID NO: 1 can also comprise 20 consecutive nucleotides of SEQ ID NO: 3. Thus, the amendment is not necessary for the reasons stated by applicant and, because entry of the amendment would necessitate a new search and might raise new issues under 35 U.S.C. §112, first paragraph, the amendment will not be entered..

Continuation of 11. does NOT place the application in condition for allowance because: Applicant's arguments are predicated on entry of the amendment and, as the amendment has not been entered, are moot. It is noted with respect to the rejection under 35 U.S.C. §112, first paragraph, that the identification of claim 16 as rejected is an obvious typographical error in view of the fact that the limitations discussed in the body of the claim are those of claim 15. Likewise, the limitations of claim 23 are mistakenly attributed to claim 24 in the body of the rejection. However, it is clear from the statement of the rejection as a whole that the rejected claims are 15, 23 and 24...